TABLE 1.
Role of HRV in lung diseasesa
Clinical syndrome | Population cohort | % virus-infected subjects |
% HRV-infected subjectsb |
References | ||
---|---|---|---|---|---|---|
Sick | Well | Sick | Well | |||
Acute illness | ||||||
Bronchiolitis | Outpatient with wheezing aged <2 years | 66-68 | 25-31 | 33-45 | 11-26 | 21, 58, 66 |
Hospitalized or emergency department patient aged <2 years | 86-93 | 10-30 | 7, 42, 72 | |||
Pneumonia | Hospitalized childrenc | 55-65 | 24-45 | 48, 61, 112 | ||
Immunocompromised adultsc | 17-19 | 4-8 | 20, 39 | |||
Exacerbation of chronic lung disease | ||||||
Asthma | Outpatient children | 62-81 | 12-41 | 52-54 | 12-28 | 44, 47 |
Hospitalized children | 61-63 | 18-23 | 48-57 | 2-19 | 33, 51 | |
Outpatient adults | 44-76 | 3-13 | 18-48 | 0-13 | 2, 32, 52, 85 | |
Hospitalized adults | 26-48 | 18 | 10-35 | 4 | 29, 108 | |
COPD | Older adults | 22-64 | 12-19 | 3-36 | 0-4 | 54, 77, 96, 100, 108 |
Cystic fibrosis | Children | 28 | 16 | 105 |
Studies in the table are limited to those using molecular techniques for detection of HRV. Some of the studies mentioned in the article used diagnostic techniques that did not differentiate between HRV and enteroviruses and reported detection rates for picornaviruses. Some studies did not include control data for virus detection in well children.
Data for infections with HRV as a single viral pathogen.
Bacterial and viral pathogens codetected in some infections.